氯硝西泮与己酮可可碱复方外用制剂治疗创伤后神经病理性疼痛:一项随机双盲安慰剂对照试验的研究方案
本方案为单中心、随机、双盲、安慰剂对照、交叉设计的II期临床试验,计划入组32例创伤后外周神经病理性疼痛患者,分别接受氯硝西泮与己酮可可碱复方外用制剂或安慰剂治疗2周,洗脱期1周。主要结局为视觉模拟量表记录的每日自发性疼痛强度及刷刺激诱发的机械性异常性疼痛程度,次要结局包括疼痛缓解评分和点状痛觉过敏面积变化。
要点
- 氯硝西泮与己酮可可碱均为血管扩张剂,协同增强组织灌注和氧合,在啮齿类神经病理性疼痛模型中显示抗伤害感受特性。
- 本试验为首个在创伤后神经病理性疼痛患者中评估该复方外用制剂疗效与安全性的II期临床研究。
- 交叉设计每例患者先后接受复方制剂和安慰剂各2周,洗脱期1周,以减少个体间差异。
核心结论
- 该研究方案旨在评估氯硝西泮与己酮可可碱复方外用制剂治疗创伤后外周神经病理性疼痛的疗效和安全性,目前尚无该适应症的人体临床证据。
研究设计与样本
- 单中心、随机、双盲、安慰剂对照、交叉设计的II期临床试验方案,计划入组32例创伤后外周神经病理性疼痛患者。
- 每例患者按随机顺序先后接受复方制剂或安慰剂外用治疗各2周,两次治疗间洗脱期为1周,总研究时长5周。
主要发现
- 方案未报告试验结果;背景提及该复方外用制剂在健康志愿者实验性诱发的神经病理性疼痛中有效降低自发性疼痛和诱发痛强度。
- 背景提及氯硝西泮和己酮可可碱单用及联用在啮齿类神经病理性疼痛模型中均显示抗伤害感受特性。
关键数值与推荐
- 主要结局指标为每日疼痛日记中视觉模拟量表记录的自发性疼痛强度,以及刷刺激诱发的机械性异常性疼痛程度。
- 次要结局指标包括疼痛缓解评分和点状痛觉过敏面积变化。
临床怎么用
- 目前仅为研究方案,尚无临床推荐;若试验证实有效,该复方外用制剂可能为创伤后神经病理性疼痛提供局部治疗选择。
- 该试验可为其他增强组织氧合的外用药物治疗外周神经病理性疼痛提供研究依据。
局限性
- 方案为单中心、小样本(32例)II期试验,结果需后续更大规模研究验证。
- 原文未报告该复方外用制剂在创伤后神经病理性疼痛患者中的疗效或安全性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: First-line pharmacotherapy for neuropathic pain entails the use of systemic antidepressants and anticonvulsants. These drugs are not optimally effective and poorly tolerated, especially for older patients with comorbid conditions. Given the high number of such patients, there is a need for a greater repertoire of safer and more effective analgesics. Clonidine and pentoxifylline are vasodilator agents that work synergistically to enhance tissue perfusion and oxygenation. The topical administration of these drugs, individually and in combination, has shown anti-nociceptive properties in rodent models of neuropathic pain. A topically-administered combination of clonidine and pentoxifylline also effectively reduced the intensity of both spontaneous and evoked pain in healthy volunteers with experimentally-induced neuropathic pain. The next step in advancing this formulation to clinical use is the undertaking of a phase II clinical study to assess its efficacy and safety in neuropathic pain patients. METHODS/DESIGN: This is a study protocol for a randomized, double-blind, placebo-controlled, phase II clinical trial with a cross-over design. It is a single-centered, 5-week study that will enroll a total of 32 patients with post-traumatic peripheral neuropathic pain. Patients will be treated topically with either a combination of clonidine and pentoxifylline or placebo for a period of 2 weeks each, in randomly assigned order across patients, with an intervening washout period of 1 week. The primary outcome measures of the study are the intensity of spontaneous pain recorded daily in a pain diary with a visual analog scale, and the degree of mechanical allodynia evoked by a brush stimulus. The secondary outcome measures of the study include scores of pain relief and change in the area of punctate hyperalgesia. This trial has been prospectively registered with ClinicalTrials.gov on November 1, 2017. ClinicalTrials.gov Identifier: NCT03342950 . DISCUSSION: The analgesic use of topical treatment with clonidine and pentoxifylline in combination has not been investigated in post-traumatic neuropathic pain. This study could generate the first evidence for the efficacy and safety of the formulation in alleviating pain in patients with neuropathic pain. Furthermore, this trial will provide objective grounds for the investigation of other agents that enhance tissue oxygenation in the topical treatment of peripheral neuropathic pain. TRIAL REGISTRATION: This trial has been registered with ClinicalTrials.gov owned by NIH's US National Library of Medicine. ClinicalTrials.gov NCT03342950 . Registered on November 1, 2017 (trial was prospectively registered). PROTOCOL VERSION AND IDENTIFIERS: This is protocol version 5, dated June 2018. McGill University Health Center (MUHC) Reaseach Ethics Board (REB) identification number: TTNP 2018-3906.
引用
- Fulas OA, Laferrière A, Ware DMA, et al. The effect of a topical combination of clonidine and pentoxifylline on post-traumatic neuropathic pain patients: study protocol for a randomized, double-blind placebo-controlled trial. Trials. 2021. PMID: 33596969. doi:10.1186/s13063-021-05088-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。